Aspirin/niacin

Drug Profile

Aspirin/niacin

Alternative Names: CER-627

Latest Information Update: 10 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cerenis Therapeutics
  • Class Nicotinic-acids; Salicylic acids
  • Mechanism of Action Cyclooxygenase inhibitors; GPR109A receptor agonists; GPR109B receptor agonists; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dyslipidaemias

Most Recent Events

  • 24 Jun 2010 Phase-I clinical trials in Dyslipidaemias in USA (PO)
  • 24 Jun 2010 Cerenis Therapeutics completes two phase I trials in volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top